Thomas Frisell
0000-0002-5735-9626
Karolinska Institute
12 papers found
Refreshing results…
Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies
Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Response to: ‘Inflammatory and non-inflammatory triggers of acute coronary syndromes’ by Eyuboglu
Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
Missing publications? Search for publications with a matching author name.